New publication enabled by Attana technology to understand surface composition and kinetics of ion liquids at surfaces
In a second publication in Langmuir from the group of Prof. Mark Rutland at KTH, Royal Institute of Technology Attana´s technology is further applied to understand the processes occurring at a surface in non aqueous ionic liquid solutions. This is of high importance to understand when developing new lubricants, particularly new smart lubricants addressable with electric fields – tribotronics. Additionally, Attana is interested in this research since ionic interactions are of growing importance when developing new pharmaceutical drugs.
A new understanding of the electro-response has been developed. It indicates that the ions form full monolayers which can be used to tune different surface phenomenon, such as friction and molecular adsorption. This is of major relevance when developing new lubricants that shall both minimize friction and protect surface against e.g. wear and corrosion. Importantly the results provide unique insight for the response times under electric fields, which has importance for other energy intensive applications such as batteries and capacitors.
For Attana the research of Prof Rutland is important not only for it´s direct applications into other markets such as tribology, it also provides valuable information on assays development and data analysis in drug development. Understanding the impact on ionic forces is important when designing new implants or developing new drugs. It can be used to eliminate unwanted off-target interactions as well as increase target specificity. The experiments performed has utilized Attana´s Emobilization technology, originally developed for immobilization of very negatively charged biomolecules, e.g. certain human peptides
For more information, please contact:
Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact sales@attana.com.
Tags:
